CV301

CV301 is a poxviral-based cancer vaccine designed to stimulate an immune response against tumors expressing the human tumor-associated antigens carcinoembryonic antigen (CEA) and mucin 1 (MUC1). The vaccine uses a prime-boost strategy involving two recombinant viral vectors: modified vaccinia Ankara-Bavarian Nordic (MVA-BN) for priming and fowlpox virus (FPV) for boosting. By encoding both CEA and MUC1, CV301 aims to induce T-cell responses targeting these antigens on cancer cells. It has been evaluated in combination with immune checkpoint inhibitors such as anti-PD-1 therapies (nivolumab, pembrolizumab), durvalumab, and atezolizumab across multiple solid tumor types including non-small cell lung cancer, metastatic colorectal cancer, urothelial carcinoma, and others. Clinical trials have demonstrated that CV301 is generally safe and immunologically active; however, efficacy results have varied by indication[5][6][8].